Abstract 1008P
Background
TACE is the first choice for patients (pts) with intermediate-stage HCC. Numerous studies have demonstrated the limited survival benefit of TACE alone in pts with stage BCLC B, particularly in tumor beyond up-to-seven criteria. Single immunotherapy agent showed a certain effect for unresectable HCC pts, but still with unsatisfactory. This study was designed to explore the efficacy and safety of sintilimab plus cTACE for HCC with stage BCLC B (or stage CNLC IIa-IIb) beyond up-to-seven criteria.
Methods
This is a single-arm, phase II study(NCT04842565). Eligible HCC pts were treated cTACE and sintilimab (200mg, IV, Q3W). The first sintilimab dose was given after the first cTACE, and then every 3 weeks. The primary objectives were safety and progression-free survival (PFS). Secondary objectives included ORR assessed by both RECIST v1.1 and mRECIST v1.1, overall survival (OS), and disease control rate (DCR).
Results
From Oct 2020 to Feb 2023, 20 pts were enrolled with a median age of 62 years. All pts were BCLC stage B, and 45.0% (9/20) were CNLC IIa stage, 55.0% (11/20) were IIb stage. At median follow-up duration of 9.0 months, the ORR was 30.0%(95% CI: 14.6%-51.9%) per RECIST, and 60% (95%CI: 38.7%-78.1%) per mRECIST. The DCR was 95.0% (95% CI: 76.4%-99.1%) per both RECIST and mRECIST. Median PFS(by both RECIST and mRECIST) was 7.95 months (95% CI: 2.7-NA), and the median OS was not reached. Four pts converted to curative surgical resection. The optimal cut-off value of PLR(platelet-to-lymphocyte ratio) predicted tumor shrinkage was 100. Low PLR were associated with more tumor shrinkage. The most common TRAEs were hypothyroidism (37.5%), elevated aspartate aminotransferase (10.0%), rash(5.0%). Only one patient experienced grade 3 TRAE(myocarditis) and no treatment-related deaths were reported.
Conclusions
Combination of Sintilimab and cTACE showed promising antitumor activity and manageable toxicity in pts with HCC with BCLC stage B (CNLC stage IIa-IIb) beyond up-to-seven criteria. The PLR is promising predictor for tumor shrinkage in HCC. These strategy should be validated in a large randomized controlled trial.
Clinical trial identification
NCT04842565.
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan hospital affiliated to Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18